Eton Pharmaceuticals, Inc. Operating Lease, Liability, Noncurrent
Eton Pharmaceuticals, Inc. (ETON) had Operating Lease, Liability, Noncurrent of $1.08 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-13
- 2026-06-30: Operating Lease, Liability, Noncurrent $1.08M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $440.00K.
- 2025-12-31: Operating Lease, Liability, Noncurrent $460.00K.
- 2025-09-30: Operating Lease, Liability, Noncurrent $480.00K.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $1.08M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $440.00K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $460.00K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $480.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $492.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $87.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $107.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $126.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $145.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 |
| 2023-12-31 | $22.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $44.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $66.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $86.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $107.00K 10-K · filed 2024-03-14 |
| 2021-12-31 | $15.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $36.00K 10-Q · filed 2021-11-16 |
| 2021-06-30 | $58.00K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $79.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $99.00K 10-K · filed 2022-03-16 |
| 2019-12-31 | $19.00K 10-K · filed 2021-03-16 |
| 2019-09-30 | $52.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $86.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $119.00K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |